Many companies just iterate indefinitely without ever making progress toward an actual drug,” said one biotech VC on a panel ...

Negative data cost AbbVie billions of dollars in market value and convinced analysts Bristol Myers had placed a better bet in ...

A tale of two multi-billion schizophrenia deals, AstraZeneca touts strong sales while deflecting questions about an ...

If it does prove to be the end of emraclidine for schizophrenia, that looks set to benefit Bristol-Myers Squibb, which ended ...

Yet, AbbVie’s emraclidine has floundered where Karuna prospered. AbbVie’s phase 2 trials tested emraclidine as a once-daily, oral monotherapy in adults with schizophrenia experiencing an acute ...

Axsome Therapeutics' Q3 2024 earnings report shows a revenue beat with $104.8m. See why I think selling AXSM stock on any ...

This was partly offset by a 1% rise in the company’s revenue from $46 billion to $47 billion over the same period; and a 4.1% ...

The shocking failure of AbbVie’s emraclidine has investors questioning the Big Pharma’s long-term neuroscience strategy, ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Bristol-Myers Squibb Co (NYSE:BMY) shares are trading higher Monday. The stock appears to be reacting positively after AbbVie ...

AbbVie faces setback as schizophrenia trial for emraclidine fails, but still has potential with other assets from Cerevel.

BMY has been having a good run for the past three months. The stock recently touched a 52-week high. We believe there is more ...